GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (OTCPK:LOVFF) » Definitions » Asset Turnover

LOVFF (Cannara Biotech) Asset Turnover : 0.15 (As of Aug. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Cannara Biotech's Revenue for the three months ended in Aug. 2024 was $16.87 Mil. Cannara Biotech's Total Assets for the quarter that ended in Aug. 2024 was $111.08 Mil. Therefore, Cannara Biotech's Asset Turnover for the quarter that ended in Aug. 2024 was 0.15.

Asset Turnover is linked to ROE % through Du Pont Formula. Cannara Biotech's annualized ROE % for the quarter that ended in Aug. 2024 was 27.14%. It is also linked to ROA % through Du Pont Formula. Cannara Biotech's annualized ROA % for the quarter that ended in Aug. 2024 was 15.17%.


Cannara Biotech Asset Turnover Historical Data

The historical data trend for Cannara Biotech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Asset Turnover Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Asset Turnover
Get a 7-Day Free Trial 0.04 0.24 0.33 0.42 0.55

Cannara Biotech Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.14 0.14 0.13 0.15

Competitive Comparison of Cannara Biotech's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Asset Turnover falls into.



Cannara Biotech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Cannara Biotech's Asset Turnover for the fiscal year that ended in Aug. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Aug. 2024 )/( (Total Assets (A: Aug. 2023 )+Total Assets (A: Aug. 2024 ))/ count )
=59.867/( (105.002+113.306)/ 2 )
=59.867/109.154
=0.55

Cannara Biotech's Asset Turnover for the quarter that ended in Aug. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Aug. 2024 )/( (Total Assets (Q: May. 2024 )+Total Assets (Q: Aug. 2024 ))/ count )
=16.87/( (108.852+113.306)/ 2 )
=16.87/111.079
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Cannara Biotech  (OTCPK:LOVFF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Cannara Biotech's annulized ROE % for the quarter that ended in Aug. 2024 is

ROE %**(Q: Aug. 2024 )
=Net Income/Total Stockholders Equity
=16.856/62.119
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(16.856 / 67.48)*(67.48 / 111.079)*(111.079/ 62.119)
=Net Margin %*Asset Turnover*Equity Multiplier
=24.98 %*0.6075*1.7882
=ROA %*Equity Multiplier
=15.17 %*1.7882
=27.14 %

Note: The Net Income data used here is four times the quarterly (Aug. 2024) net income data. The Revenue data used here is four times the quarterly (Aug. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Cannara Biotech's annulized ROA % for the quarter that ended in Aug. 2024 is

ROA %(Q: Aug. 2024 )
=Net Income/Total Assets
=16.856/111.079
=(Net Income / Revenue)*(Revenue / Total Assets)
=(16.856 / 67.48)*(67.48 / 111.079)
=Net Margin %*Asset Turnover
=24.98 %*0.6075
=15.17 %

Note: The Net Income data used here is four times the quarterly (Aug. 2024) net income data. The Revenue data used here is four times the quarterly (Aug. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Cannara Biotech Asset Turnover Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .